Activity Preview

Live

DSM 5: What You Need to Know

Activity Type:

  • On Demand Plus


Release Date: 6/9/2013

Expiration Date: 6/30/2021

  • AMA PRA Category 1: 6
  • Participation: 6

Register

Overview

The most authoritative online course on the DSM-5 presented by the DSM-5 Task Force chair and vice-chair, Drs. David J. Kupfer and Darrel A. Regier, and supplemented by presentations from chairs or members of the 13 DSM-5 Work Groups, who provide explanations regarding changes in their respective diagnostic classes and offer specific guidance about implementation in clinical care and research.

The release of DSM-5 marks the first major revision to the classification of and diagnostic criteria for mental disorders since DSM-IV was released in 1994. The focus of this online course is to educate clinicians, researchers and healthcare providers on the major changes from DSM-IV to DSM-5, including diagnosis-specific changes (e.g., criteria revisions) as well as broader, manual-wide changes (e.g., revised chapter ordering, use of dimensional assessments, integration of neuroscience and developmental material across the manual). The primary emphasis is on ensuring clinicians and healthcare providers understand how these changes might impact patient care and knowing what modification might be necessary to implement these revisions in their practice. Presentations will also address potential scientific implications and assist researchers in understanding how DSM-5 might impact the study of mental disorders. 

The course consists of content recorded at the APA Annual Meeting in May 2013. Handouts providing key details of the changes as well as slide handouts are available for download.

Pricing

  • General Member - $124.50
  • Resident-Fellow Member - $62.25
  • Medical Student Member - $124.50
  • Non-Member - $249.00

Course Agenda

This course is part of the APA’s On Demand Plus series.  On Demand Plus courses offer a deeper exploration of material through rich content and enhanced features.  On Demand Plus courses are multi-modular and are typically completed over a longer time period. The course agenda includes: 

  • Course Introduction
  • Use of the Manual
  • Section III (Emerging Measures and Models)
  • Neurodevelopmental Disorders
  • Depressive and Bipolar Disorders
  • Trauma and Dissociative Disorders
  • Anxiety and OCD Disorders
  • Somatic Disorders
  • Eating Disorders
  • Sleep Disorders
  • Psychotic Disorders
  • Sexual Dysfunction, Gender Dysphoria, and Paraphilic Disorders
  • Substance-Related Disorders
  • Disruptive, Impulse Control, Conduct and Other Childhood Disorders
  • Neurocognitive Disorders
  • Personality Disorders

Educational Objectives

  • List the primary significant changes in the classification of and diagnostic criteria for mental disorders from DSM-IV to DSM-5
  • Discuss some of the major clinical modifications that might be needed to implement the major changes in DSM-5
  • Describe some of the important research implications resulting from changes in DSM-5
  • Transition from DSM IV to DSM 5 in a work setting

Target Audience

Psychiatrists and other physicians; all clinicians interested in DSM-5.

Estimated Time to Complete

  • Estimated Time to Complete: 6 Hours
  • Release Date: June 2013
  • Review Date: April 2019
  • Expiration Date: June 30, 2021

How to Earn Credit

Participants who wish to earn AMA PRA Category 1 Credit ™ or a certificate of participation may do so by completing all sections of the course. A multiple choice quiz is provided based on the content. A passing score of 80% must be achieved. Retakes are available for the test. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (non-physicians) showing the date of completion and hours earned.

Continuing Education Credit

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this enduring CME activity for a maximum of 6 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Planner Disclosures

 Presenters

  • David J. Kupfer, M.D., Chair, DSM-5 Task Force: University of Pittsburgh Medical Center, Pittsburgh, PA. Reports no financial relationships with commercial interests.
  • Darrel A. Regier, M.D., M.P.H., Vice-Chair, DSM-5 Task Force; Division of Research & American Psychiatric Institute for Research and Education, American Psychiatric Association, Arlington, VA. Reports no financial relationships with commercial interests.
  • Susan E. Swedo, M.D.,Chair, DSM-5 Neurodevelopmental Disorders Workgroup;Chief, Pediatrics and Developmental Neuropsychiatry Branch, Intramural Research Program, NIMH. Reports no financial relationships with commercial interests.
  • Jan Fawcett, M.D., Chair,DSM-5 Mood Disorders Work Group;Professor of Psychiatry, University of New Mexico School of Medicine, Albuquerque, NM.  Disclosure: Expert Testimony: one case involving Apotex
  • Roberto Lewis-Fernández, M.D., DSM-5 Anxiety, Obsessive-Compulsive Spectrum, Post-Traumatic, and Dissociative Disorders Work Group; Associate Professor of Clinical Psychiatry, Columbia College of Physicians & Surgeons, New York State Psychiatric Institute. Disclosure: Grant/Research Support: Eli Lilly, Eli Lilly and Company, Forest Laboratories, Inc., Transcept Pharmaceuticals Inc. Speakers Bureau/Speaker Honoraria, Merck Manual (Future), Speaking honoraria and travel reimbursement from academic institutions and professional organizations 
  • Katharine A. Phillips, M.D., Chair, DSM-5 Anxiety, Obsessive-Compulsive Spectrum, Post-Traumatic, and Dissociative Disorders Work Group; Professor of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Director of Research for Adult Psychiatry, Director, Body Dysmorphic Disorder Program, Rhode Island Hospital. Disclosure: Research support:Forest Laboratories (medication for NIMH-funded study), Transcept PharmaceuticalsConsulting: Janssen Research and Development
  • Joel E. Dimsdale, M.D., Chair, DSM-5 Work Group on Somatic Symptom Disorders; Distinguished Professor of Psychiatry Emeritus and Research Professor, UCSD. Reports no financial relationships with commercial interests 
  • B. Timothy Walsh, M.D., Chair, DSM-5 Eating Disorders Work Group; Professor of Pediatric Psychopharmacology, Department of Psychiatry, College of Physicians & Surgeons, Columbia University. Disclosure: Grant/Research Support, AstraZeneca Pharmaceuticals
  • Charles F. Reynolds III, M.D., Chair, DSM-5 Sleep-Wake Disorders Work Group;Professor of Geriatric Psychiatry, Professor of Neuroscience, University of Pittsburgh; Director, Aging Institute, UPMC and University of Pittsburgh. Disclosure: Pharmaceuticals for NIH-sponsored research:Forest Laboratories, Pfizer, Lilly, Bristol-Myers Squibb
  • William T. Carpenter, M.D., Chair, DSM-5 Psychosis Work Group;Professor of Psychiatry and Pharmacology, Maryland Psychiatric Research Center, University of Maryland School of Medicine. Disclosure: Scientific Advisor: Genentech/Roche.Patent: (no personal funds): European Regional Patent Number 1487998 (June 6, 2007) “Methods for Diagnosing and Treating Schizophrenia”
  • Kenneth J. Zucker, Ph.D., Chair, DSM-5 Workgroup on Sexual and Gender Identity Disorders; Professor, Department of Psychiatry, University of Toronto. Reports no financial relationships with commercial interests.
  • Charles P. O’Brien, M.D., Ph.D., Chair, DSM-5 Workgroup on Substance Related Disorders; Professor of Psychiatry, University of Pennsylvania. Disclosure: Consultant/Advisory Board: Embera NeuroTherapeutics, Inc., Alkermes
  • David Shaffer, F.R.C.P., F.R.C.Psych., Chair, DSM-5 ADHD and Disruptive Behavior Disorders Work Group; Professor of Psychiatry and Pediatrics, Columbia University/New York State Psychiatric Institute. Reports no financial relationships with commercial interests.
  • Ronald C. Petersen, Ph.D., M.D., DSM-5 Neurocognitive Disorders Work Group; Department of Neurology, Mayo Clinic College of Medicine, Rochester, MN. Disclosure: Data Monitoring Committee: Pfizer, Inc., Janssen Alzheimer Immunotherapy, Elan Pharmaceuticals. Consultant: GE Healthcare. CME presentation: Novartis.
  • Andrew E. Skodol, M.D., Chair, DSM-5 Personality Disorders Work Group;University of Arizona College of Medicineand the Columbia University College of Physicians and Surgeons. Reports no financial relationships with commercial interests.
  • William E. Narrow, M.D., M.P.H., DSM-5 Task Force Research Director, DSM-5 Task Force Research Group, Chair, Other Conditions That May Be a Focus of Clinical Attention Work Group, Chair Diagnostic Spectra Study Group; Impairment and Disability Study Group; Gender and Cross-Cultural Study Group; Diagnostic Assessment Instruments Study Group; American Psychiatric Institute for Research and Education (APIRE), Arlington, VA. Reports no financial relationships with commercial interests.

Presentation Outline

  • David J. Kupfer, M.D. – Orientation to course, overview of DSM-5 chapter organization
  • Darrel Regier, M.D., MPH – Use of the manual
  • Susan Swedo, M.D. – Neurodevelopmental Disorders
  • Jan Fawcett, M.D. – Depressive and Bipolar Disorders 
  • Roberto Lewis-Fernández, M.D. – Trauma and Dissociative Disorders
  • Katharine A. Phillips, M.D. – Anxiety and OCD Disorders 
  • Joel Dimsdale, M.D. – Somatic Disorders
  • Timothy Walsh, M.D. – Eating Disorders
  • Charles F. Reynolds, M.D. – Sleep Disorders
  • William T. Carpenter, M.D. – Psychotic Disorders
  • Kenneth J. Zucker, Ph.D. – Sexual Dysfunctions, Gender Dysphoria, and Paraphilic Disorders
  • Charles O’Brien, M.D., Ph.D. – Substance-Related Disorders 
  • David Shaffer, M.D. – Disruptive, Impulse Control, and Conduct Disorders
  • Ronald C. Petersen, M.D., Ph.D. – Neurocognitive Disorders
  • Andrew Skodol, M.D. – Personality Disorders
  • Darrel A. Regier, M.D., MPH and William E. Narrow, M.D., MPH – Disability assessment, v/z codes, and forensic issues
  • Final discussion / wrap-up

Program Planners

  • Matthew J. Friedman, M.D., Ph.D., Chair, DSM-5 Sub-Work Group on Trauma and Stress-Related Disorders; National Center for PTSD, Geisel School of Medicine at Dartmouth. Reports no financial relationships with commercial interests.
  • Deborah J. Hales, M.D., Former Director, APA Division of Education, Arlington VA. CME Program Planner. Reports no financial relationships with commercial interests.
  • Tristan Gorrindo, M.D., Director, APA Division of Education, Arlington VA. CME Program Planner. Reports no financial relationships with commercial interests.

Accessibility for Participants with Disabilities

The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.

Hardware/Software Requirements

Hardware/Software Specifications: 
This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:

  • Flash Player: Adobe Flash Player 10.1+ 
  • Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+ 
  • Operating System: Windows XP+ or Mac OS X 10.4+ 
  • Internet Connection: 1 Mbps or higher

Minimum Requirements:

  • Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
  • Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

For assistance: Contact educme@psych.orgfor questions about this course  |  Contact learningcenter@psych.org for technical assistance

All materials copyright American Psychiatric Association ©2013

Register